Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC.

Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.

2.

Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.

Kansal AR, Zheng Y, Pokora T, Sorensen SV.

Best Pract Res Clin Haematol. 2013 Jun;26(2):225-37. doi: 10.1016/j.beha.2013.07.012. Epub 2013 Aug 1. Review.

PMID:
23953910
3.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
4.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
5.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
6.

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

Harris K, Mant J.

Int J Clin Pract. 2013 Jul;67(7):647-55. doi: 10.1111/ijcp.12177. Epub 2013 Apr 28. Review.

7.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Berman JP, Halperin JL.

Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Review.

PMID:
23466966
8.

[Improvements in oral anticoagulant therapy for atrial fibrillation].

Briongos Figuero S, García Santos-Gallego C, Badimón JJ.

Med Clin (Barc). 2013 Dec 7;141(11):487-93. doi: 10.1016/j.medcli.2013.02.015. Epub 2013 Apr 16. Review. Spanish.

PMID:
23597953
9.

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.

Aguilar MI, Kuo RS, Freeman WD.

Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001. Review.

PMID:
23896498
10.

Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.

Adcock AK, Lee-Iannotti JK, Aguilar MI, Hoffman-Snyder CR, Wingerchuk DM, Wellik KE, Demaerschalk BM.

Neurologist. 2012 Mar;18(2):102-7. doi: 10.1097/NRL.0b013e318247bcb6. Review.

PMID:
22367842
11.

New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.

Bhimani AA, Hong M.

Rev Recent Clin Trials. 2013 Jun;8(2):78-85. Review.

PMID:
23859143
12.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
13.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
14.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.

Contractor T, Levin V, Martinez MW, Marchlinski FE.

Postgrad Med. 2013 Jan;125(1):34-44. doi: 10.3810/pgm.2013.01.2622. Review.

PMID:
23391669
15.

[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].

Kovács T.

Orv Hetil. 2014 Oct 19;155(42):1655-60. doi: 10.1556/OH.2014.30021. Review. Hungarian.

PMID:
25305723
16.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
17.

Novel oral anticoagulants in secondary prevention of stroke.

Diener HC, Easton JD, Hankey GJ, Hart RG.

Best Pract Res Clin Haematol. 2013 Jun;26(2):131-9. doi: 10.1016/j.beha.2013.07.007. Epub 2013 Jul 30. Review.

PMID:
23953901
18.

[Evidence of novel oral anticoagulants (NOAC)].

Kitazono T.

Rinsho Shinkeigaku. 2013;53(11):992-3. Review. Japanese.

PMID:
24291856
19.

Target-specific oral anticoagulants: practice issues for the clinician.

Plitt A, Giugliano RP.

Hosp Pract (1995). 2014 Aug;42(3):48-61. doi: 10.3810/hp.2014.08.1117. Review.

PMID:
25255406
20.

Switching between oral anticoagulants.

Strasser KM, Qasem A, Madhusudhana S.

Hosp Pract (1995). 2014 Aug;42(3):68-74. doi: 10.3810/hp.2014.08.1119. Review.

PMID:
25255408

Supplemental Content

Support Center